Comparative Pharmacology
Head-to-head clinical analysis: NORLUTIN versus PROVERA.
Peer-Reviewed Evidence
Head-to-head clinical analysis: NORLUTIN versus PROVERA.
NORLUTIN vs PROVERA
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Synthetic progestin that binds to progesterone receptors, suppressing gonadotropin secretion and altering endometrial lining.
Provera (medroxyprogesterone acetate) is a progestin that binds to progesterone receptors, suppressing gonadotropin secretion, inhibiting endometrial growth, and inducing secretory changes in the endometrium. It also has antigonadotropic effects by reducing LH and FSH release from the pituitary.
5 mg orally three times daily for endometriosis; 5 mg orally daily from day 5 to day 25 of menstrual cycle for amenorrhea.
Oral: 5-10 mg daily for 5-10 days for secondary amenorrhea; 5-10 mg daily for 12-14 days per cycle in combination with estrogen for endometrial hyperplasia; 400-1000 mg/day IM monthly for endometriosis.
None Documented
None Documented
Terminal elimination half-life: 5–14 hours (mean ~8 hours). Clinical context: short half-life necessitates daily dosing for contraceptive efficacy.
Terminal elimination half-life is approximately 12-17 hours for medroxyprogesterone acetate (oral). With depot intramuscular injection, the half-life is extended to approximately 50 days due to slow absorption from the injection site.
Mainly renal as glucuronide and sulfate conjugates; approximately 70% renal, 30% fecal/biliary.
Renal (50-60% as metabolites), biliary/fecal (30-40%). Less than 1% excreted unchanged.
Category C
Category C
Progestin
Progestin